Phase II evaluation of LY2603618, a first-generation CHK1...

Investigational New Drugs 2016 / 10 Vol. 34; Iss. 5

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

Scagliotti, Giorgio, Kang, Jin Hyoung, Smith, David, Rosenberg, Richard, Park, Keunchil, Kim, Sang-We, Su, Wu-Chou, Boyd, Thomas E., Richards, Donald A., Novello, Silvia, Hynes, Scott M., Myrand, Scot
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
34
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-016-0368-1
Date:
October, 2016
File:
PDF, 771 KB
english, 2016
Conversion to is in progress
Conversion to is failed